Petter Segelman Lindqvist

Chairman & CEO

C-suiteM

FI·FIN-FSA

Isofol Medical AB (publ)Isofol Medical AB (publ)

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the full record of transactions filed by Petter Segelman Lindqvist, Chairman & CEO. Director active across 2 companies, notably Isofol Medical AB (publ). Aggregated, 2 reports have been logged. The latest transaction was disclosed on 2 July 2025 — Purchase. Regulator: FIN-FSA. The full history is free.

Declarations2 total

Executives●PurchaseIIsofol Medical AB (publ)32FIN-FSA

P

Petter Segelman LindqvistVerkställande direktör (VD)

€2,0622,412 shares@ €0.8550.0008% mcap88.4% of flow

BTU (betald tecknad unit)

FI:A003Q427-1·2 Jul 2025

Ideal exit: 29 Mar 2026 (T+270)

FIN-FSA ↗

Executives●SaleIIsofol Medical AB (publ)25FIN-FSA

P

Petter Segelman LindqvistVerkställande direktör (VD)

€27133,408 shares@ €0.00810.0001% mcap11.6% of flow

Teckningsrätt/Uniträtt

FI:A003Q152-1·19 Jun 2025

FIN-FSA ↗

2 of 2 declarations

About Petter Segelman Lindqvist

Petter Segelman Lindqvist is the CEO of Isofol Medical AB (publ), an innovative company in the biotechnology sector. Under his leadership, Isofol Medical focuses on developing innovative treatments for cancer. Petter brings extensive experience in management and product development, enabling him to guide the company to new heights. His commitment to innovation and research is essential for Isofol Medical's success.